Core Insights - Arcutis Biotherapeutics announced positive results from the Phase 3 open-label extension study of ZORYVE (roflumilast) cream 0.05% for treating mild-to-moderate atopic dermatitis in children aged 2 to 5 years, showing sustained efficacy and safety over 56 weeks [1][7][10] Study Results - The INTEGUMENT-OLE study demonstrated that ZORYVE cream 0.05% is safe and well-tolerated, with efficacy improving over time [1][7] - 63.1% of participants achieved a Validated Investigator Global Assessment score of Clear or Almost Clear at Week 56 [6] - 71.9% of children continuing treatment and 76.0% of those switching from vehicle to ZORYVE cream achieved at least a 75% reduction in Eczema Area and Severity Index [6][8] Safety Profile - Treatment-Emergent Adverse Events (TEAEs) were reported in 49.8% of participants, with most being mild or moderate [4] - Serious Adverse Events (SAEs) occurred in 3.2% of participants, none of which were treatment-related [4] - Over 97% of participants showed no evidence of local irritation, and severe burning or stinging sensations were reported in ≤1.8% of participants [5] Treatment Regimen - Children achieving clear skin were transitioned to a proactive twice-weekly application, maintaining disease control for a median duration of approximately 8 months [7][9] - The study included 562 participants who initially applied ZORYVE cream once daily, with 30.2% transitioning to the twice-weekly regimen [3][9] Industry Context - Atopic dermatitis affects approximately 9.6 million children in the U.S., highlighting the need for effective treatments in this demographic [2][11] - ZORYVE is recognized as the number one prescribed branded topical therapy for atopic dermatitis, seborrheic dermatitis, and plaque psoriasis [13]